What's in ikfe-CRO GmbH's pipeline?

ikfe-CRO GmbH has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ikfe-CRO GmbH's portfolio?

Top competitors by shared drug class: Meir Medical Center, Sheba Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ikfe-cro-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

ikfe-CRO GmbH — Portfolio Competitive Intelligence Brief

ikfe-CRO GmbH pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Metformin and Saxagliptin	Metformin and Saxagliptin	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Meir Medical Center · 1 shared drug class
Sheba Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ikfe-CRO GmbH:

Cite this brief

Drug Landscape (2026). ikfe-CRO GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ikfe-cro-gmbh. Accessed 2026-05-16.